Marker to Present at Two Upcoming Cellular Therapy Conferences
HOUSTON, Oct. 18, 2018 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming cellular therapy conferences. Mr. Hoang will present a talk titled, "Moving Beyond CAR-T: Non-Engineered Multi-Antigen Specific T Cells Can Drive Significant Therapeutic Benefit for Patients with Lymphoma, Myeloma, and AML," at the PDA Cell and Gene Therapy Conference, to be held October 23, 2018, in Bethesda, MD, and will participate on a panel titled, "Future of Cellular Therapy - The 'Living Drug,'" at the offices of Mintz Levin on October 25, 2018, in New York City.
PDA Cell and Gene Therapy Conference:
Presentation Title: Moving Beyond CAR-T: Non-Engineered Multi-Antigen Specific T Cells Can Drive Significant Therapeutic Benefit for Patients with Lymphoma, Myeloma, and AML
Date: Tuesday, October 23, 2018
Location: Hyatt Regency Bethesda; Bethesda, MD
Time: 4:00pm (ET): Presentation
5:00pm (ET): Discussion Panel
Panel Title: Future of Cellular Therapy - The "Living Drug"
Date: Thursday, October 25, 2018
Location: Mintz Levin Offices, New York, NY
Time: 5:30pm (ET)
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
For additional information, please visit: www.markertherapeutics.com
To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to any inability to recognize the anticipated benefits of the merger and the financing as well as the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
SOURCE Marker Therapeutics, Inc.